Small short-term clinical trials have shown that the FDA-approved anti-obesity glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improve insulin resistance in PCOS patients (70) and may be superior to metformin (71). Here, GLP1R is linked to Insulin resistance.